For elderly or comorbid patients, the high toxicity of powerful, time-limited combination therapies can outweigh their efficacy. A less harsh, continuous monotherapy is often preferable as it better preserves quality of life, even if it doesn't offer a treatment-free interval or a theoretical "100% life back."

A common assumption that older patients may prefer simpler, continuous medication regimens is often incorrect. Clinical experience shows that the vast majority of patients, regardless of age, are interested in a time-limited therapy option, provided it can be delivered conveniently without infusions.

For older, transplant-ineligible patients, well-tolerated, long-term regimens from trials like CFIUS shift the treatment goal. Success is defined as managing myeloma so effectively that patients are more likely to die of other age-related causes, effectively outliving their cancer.

The CLL-17 trial, the first modern head-to-head comparison of major CLL strategies, showed no difference in 3-year survival between fixed-duration and continuous therapy. This landmark finding provides strong evidence that stopping treatment is a safe and effective strategy that reduces long-term toxicity for patients.

Traditional endpoints like progression-free survival (PFS) incentivize continuous treatment. The NCI group proposes "treatment-free survival," a novel metric that quantifies time spent *off* therapy. This endpoint better captures the patient experience and rewards treatments that provide durable responses after a finite course.

The ASH-AYA-ALL guidelines explicitly state that a major goal is not only to improve survival but also to enhance quality of life during and after treatment. This includes a focus on avoiding long-term toxicities and preserving fertility, signaling a formal shift towards prioritizing the patient's long-term, healthy, and productive future beyond just curing the disease.

Long-term CML therapy success hinges on adherence. Minor intolerances and lifestyle inconveniences, which accumulate over a lifetime of treatment, are more likely to cause patients to stop therapy than the drug failing to work, compromising outcomes.

Despite the appeal of stopping treatment, a key insight from clinical practice is that patients' most critical question remains which therapy offers the longest period of remission, often overriding factors like treatment duration and oral-only options.

The primary goal in CML is evolving from chronic management to achieving Treatment-Free Remission (TFR). This paradigm shift favors using the most potent TKIs, like asciminib, first-line to induce deep, rapid molecular responses and enable eventual therapy discontinuation.